Stock Ratings / Health Care / RNA / financials

MENS (33) NBP (38) MSLE (58) KZIA (61) ⌘ Pro Terminal →

Atrium Therapeutics Inc. (RNA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$8.27 +0.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.26

Atrium Therapeutics Inc. (RNA) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $141.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RNA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Atrium Therapeutics Inc. (NASDAQ: RNA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $8.27 (+0.12% 1D, market cap $141.3M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, RNA ranks #234 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RNA compare to MENS and NBP in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RNA carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MENS (Jyong Biotech Ltd.) holds a E grade (33/100 RQD, P/E N/A, ROIC -28.8%, cap $142.9M) and NBP (NovaBridge Biosciences) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $139.6M). Among the 5-stock peer group, RNA leads on earnings multiple (N/A) while MENS leads on capital efficiency (-28.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RNA?

▼

Per RNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002093101), Atrium Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $8.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $8.26 (-0.17%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY • 51.4% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE-1.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RNA)Realized 20D OHLCV Swing Band: ±9.8%

Deterministic 5-Pillar Attribution (55/100 Composite)

🔍 WHY RNA SCORES 55/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (27% of score)

FRED Regime × Technicals: 8% of 52W Range • RSI-14 at 52.1 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$8.21-7.3% Next Q

Q2 (-2Q)

Grade C-$7.61+5.8% Next Q

Q3 (-1Q)

Grade C-$8.05+2.7% Next Q

Current

Grade D+$8.27-0.5% Hist 90D α

Trajectory: D (47) → D+ (55)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the RNA Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 55/100 (D+) score, RNA faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($9.68) or 200D SMA ($12.06) invalidates the momentum regime and cuts Target Base ($8.16) toward Bear Floor ($6.36).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RNA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RNA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 55%NO 45%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How RNA Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$4.0M (0.1% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	0%	$0	$0	15%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RNA)

✓Walkthrough of RNA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RNA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.74%📐 HORIZONTAL RANGE

2026-11-02O $8.22H $8.64L $8.19C $8.27VOL 219.3K

RES: $15.01SUP: $6.14SMA50: $9.68SMA200: $12.06

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RNA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RNA Butterfly Map → + Track RNA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RNA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RNA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RNA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RNA)

Health Care Rank #234 of 1016 ⚔️ MENS vs RNA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RNA vs. MENS, NBP, MSLE, KZIA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Atrium Therapeutics Inc. (RNA) ranks #234 by composite RQD confidence (55/100, grade D+) and #616 by equity capitalization ($141.3M). Within this direct 5-issuer industry benchmark cohort, RNA leads on earnings valuation at N/A trailing P/E, while MENS leads on capital efficiency and profitability with -28.8% ROIC and — gross margin. KZIA currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with RNA at 55/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RNA ACTIVE Atrium Therapeutics Inc.	D+	55/100	—	—	—	+0.12%	$141.3M	Benchmark Subject
MENS Jyong Biotech Ltd.	E	33/100	—	—	-28.8%	0.00%	$142.9M	/mens-vs-rna →
NBP NovaBridge Biosciences	D-	38/100	—	—	-35.0%	-1.24%	$139.6M	/nbp-vs-rna →
MSLE Satellos Bioscience Inc.	D+	58/100	—	—	—	-1.69%	$144.6M	/msle-vs-rna →
KZIA Kazia Therapeutics Limited	C-	61/100	—	—	—	-2.52%	$135.6M	/kzia-vs-rna →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002093101

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Atrium Therapeutics Inc. (RNA) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, RNA closed FY2025 with $8.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$8.4M	—

3. RNA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does RNA compare to MENS and NBP in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for RNA?

Where is RNA trading relative to its 50-day, 200-day, and 52-week technical levels?

RNA last traded at $8.27 (+0.12% on volume of 566,651 shares), positioning the stock -14.57% below its 50-day simple moving average ($9.68) and -31.43% below its 200-day simple moving average ($12.06). Across its 52-week range of $7.49 to $16.77, RNA sits at the 8.4% percentile with a 14-day RSI of 52.1 (NEUTRAL RANGE) and an implied next-earnings move of ±9.8% ($7.46 to $9.08).

RNA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Atrium Therapeutics Inc. (RNA)?

In FY 2025 (10-K), RNA converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $4.0M in free cash flow (0.1% FCF margin).

Direct Sub-Reports: RNA RQD Cockpit RNA 12M Forecast RNA Earnings & Move RNA Dividends & DRIP RNA Insiders & 13F RNA Whale Options RNA Profit Sankey RNA News & Why

ROARABLE RATING BRIEF • RQD 55/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

RNA — Atrium Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:17:59Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, RNA scores 55 out of 100, a letter grade of D+, with the verdict label "Roarable Sell — Weak Fundamentals / Trim." The five pillars are scored as follows:

Fundamental Cash Engine: 10 / 20. The RQD inputs show ROIC of 0% and FCF yield of 0%. For a prospective investor, this means the rating does not credit the company with any current cash generation from operations.
Whale 13F Flow: 8 / 20. The rating reflects institutional accumulation and options positioning at a below-midpoint level. The source data does not provide the underlying 13F or options detail behind this score.
Insider Conviction: 9 / 20. The rating reflects SEC Form 4 and Congressional PTR cluster flow at a below-midpoint level. No individual insider or congressional transactions are itemized in the source data.
Macro Regime Fit: 15 / 20. The rating cites a beta of 1.0 and sector sensitivity. This is the strongest pillar, indicating a market-neutral volatility profile relative to the broader market.
Forensic Balance Sheet: 13 / 20. The rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 6/9, and a Debt/Equity ratio of 0.5. These are mid-range readings and do not on their own indicate distress or strength.

Taken together, the rating points to weak cash-generation metrics and limited institutional or insider conviction, partially offset by a balance sheet and volatility profile that the rating treats as moderate. The implication for an investor evaluating the stock today is that the upside case rests on factors not yet visible in reported cash flows, while the valuation tradeoffs are not resolvable from the available data because multiples are not provided. The rating's "Trim" label signals that the framework views existing exposure as a candidate for reduction rather than addition.

Business

Atrium Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company has a market capitalization of $0.1B. The source data does not describe the company's products, customers, or revenue model.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025 (filed 2025-12-31)	$0.0M	$0.0M	$0.0M	N/A	N/A	$0.0M	N/A

Per the SEC financials, reported revenue, operating income, net income, and cash for FY 2025 are each $0.0M, and EPS, FCF, and debt are reported as N/A. Gross, operating, and net margins are each 0%, and ROIC is 0% per the market data. The Roarable RQD inputs cite an Altman Z-Score of 2.5, a Piotroski F-Score of 6/9, and a Debt/Equity ratio of 0.5. The source data does not provide a multi-period trend.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, five items were captured, all tagged to RNA with a YELLOW light and a MARKET WIRE impact label:

Multiple outlets report a $50 Million Private Placement announced by Atrium Therapeutics. Reports appear from Investing News Network, PR Newswire, and citybiz, and the placement is described as advancing an RNA-based cardiology pipeline.
Yakira Capital Management publicly called on the company to launch a strategic review, curb cash spending, and explain dilutive financing. This is a governance and capital-allocation risk watch item.
Stocktwits and TradingView items are general market-coverage pages with no specific catalyst detail in the source data.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, no upstream or downstream dependencies, sector correlations, or proprietary signals are recorded. Not available in source data for supply-chain bottleneck analysis. The private placement and the activist-style call for dilution transparency are the only ripple-relevant items in the source data; their second-order effects on share count and cash runway are not quantified in the sources.

Open Questions

What is the size of the cash balance and burn rate behind the reported $0.0M cash figure, given that the placement is described as $50 Million?
What are the terms, share count, and price of the $50 Million Private Placement, and how dilutive is it?
What specific products or pipeline assets drive the RNA-based cardiology program, and at what development stage are they?
Which institutions hold RNA in the 13F data, and what options positioning underlies the whale-flow pillar score?
What are the strategic-review demands raised by Yakira Capital, and has the company responded?

RNA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Atrium Therapeutics Inc. (RNA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RNA Debate Forum (3) ↓

🟡 MARKET WIRE Investing News Network • 7h ago

Atrium Therapeutics Announces $50 Million Private Placement

Investing News Network report covering Atrium Therapeutics Inc. (RNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stocktwits • 10h ago

RNA: Atrium Therapeutics Inc. Latest Stock Price, Analysis, News and Trading Ideas

Stocktwits report covering Atrium Therapeutics Inc. (RNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 16h ago

Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing

Yahoo Finance report covering Atrium Therapeutics Inc. (RNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 19h ago

Atrium Therapeutics, Inc. Estimates – NASDAQ:RNA

TradingView report covering Atrium Therapeutics Inc. (RNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE citybiz • 22h ago

Atrium Therapeutics Secures $50 Million Private Placement to Advance RNA-Based Cardiology Pipeline

citybiz report covering Atrium Therapeutics Inc. (RNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Atrium: Initiating 'Hold'; ATR 1072 IND Clearance And 2nd Half 2027 PRKAG2 Syndrome Data

Seeking Alpha report covering Atrium Therapeutics Inc. (RNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 10h ago

Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026

Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it will present new nonclinic

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 14h ago

Atrium Therapeutics To Present New Nonclinical Data On ATR 1072 For Potential Treatment Of PRKAG2 At The American Heart Association Scientific Sessions On November 6; ATR 1072 Impacted Key Characteristics Of PRKAG2, Including Accumulation Of Cardiac Glycogen And Cardiac Hypertrophy

Data further reinforce scientific rationale for ATR 1072 targeting the root cause of PRKAG2 syndromeThe nonclinical results being presented at HCMS were generated in a new mouse model of PRKAG2 syndrome developed by

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RNA Bull vs. Bear Conversation Board — What's Your Call at $8.27?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RNA 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $8.92 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is RNA (D+ • RQD 55/100) a Buy at $8.26?

Welcome to the RNA (Atrium Therapeutics Inc.) Roar Pit. Current RQD Composite is 55/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $6.53 (-20.9%)

Spot @ $8.26

Pump the brakes on RNA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on RNA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Atrium Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $10.24 (+24.0%)

Spot @ $8.26

RNA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on RNA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $8.26 (52-wk range $7.30 - $9.11), any beat on forward guidance forces shorts and underweight funds to chase.